Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

Breast Cancer Clinical Trial

— E-SPEC  

Official title:

Prospective Observational Study to Explore the Efficacy of Eribulin as 1st-line or 2nd-line Chemotherapy in Patients With HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02551263
• Other study ID #: TRIBC1505
• Secondary ID: UMIN000018178
• Status: Completed
• Start date: July 22, 2015
• Est. completion date: July 2020

Study information

• Verified date: April 2021
• Source: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a observational study in a real-world setting, not requiring determining a dosage regimen, dose reduction criteria, rest period criteria and withdrawal criteria. The purpose of the study is to investigate the efficacy of eribulin as the first or second line chemotherapy to prolong overall survival and to explore factors affecting the survival in patients with HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer who scheduled to receive the first or second line chemotherapy in clinical practice in Japan. The total duration of the study will be a maximum of 5 years, consisting of 2-year enrollment period and 3-year observational period; the duration of patient participation will be 3 years. All patients will receive adequate treatment for breast cancer which selected by the primary physician after enrollment using the Japanese Breast Cancer Society Clinical Practice Guideline of Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Investigators at the investigational sites will enter patient data into an electronic data capture (EDC) system up to the third chemotherapy in the study. The end of the study is defined as the time the last patient completes observational period. Patients will primarily be assessed by overall survival (OS) of the first line chemotherapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 201
• Est. completion date: July 2020
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Female patients with histologically or cytologically confirmed breast cancer.

2. Patients with inoperable or recurrent metastatic breast cancer regardless of the metastatic site and number, excluding symptomatic central nervous system metastases.

3. Patients with HER2-negative disease confirmed as ISH negative or IHC 0, 1+ or 2+ (Those with IHC 2+ are eligible, if the additional ISH test results are negative. Those are ineligible who are with any positive results of estrogen receptor or progesterone receptor test on primary and recurrent lesion).

4. Patients who are resistant to hormone therapy.

5. Patients with indication for the first or second line chemotherapy in HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer who are scheduled to receive the chemotherapy.

6. Patients with the Eastern Cooperative Oncology Group (ECOG) performance status score 0-3 at the time of enrollment.

7. Patients with adequate bone marrow and major organ function judged by the primary physician.

8. Patients who have signed written informed consent to participate in this study.

Exclusion Criteria:

1. Patients with symptomatic metastasis in the central nervous system.

2. Patients with a previous history of hypersensitivity to any component of drugs which will be administered in the treatment.

3. Patients who are considered to be inappropriate for the study participation by the primary physician.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Eribulin
Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.

Locations

Country	Name	City	State
Japan	Kobe City Medical Center General Hospital	Kobe-city	Hyogo-prefecture
Japan	Kyoto University Hospital	Kyoto-city	Kyoto-prefecture

Sponsors (2)

Lead Sponsor	Collaborator
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	Kyoto Breast Cancer Research Network

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival (OS) of the first line chemotherapy		From starting date of the first line chemotherapy until date of death from any cause (up to 5 years)
Secondary	Overall survival (OS) of the second and third line chemotherapy		From starting date of each line of chemotherapy until date of death from any cause (up to 5 years)
Secondary	Progression-free survival (PFS) of the first, second and third line chemotherapy		From starting date of each line of chemotherapy until the date of first documented disease progression or date of death from any cause, whichever comes first (up to 5 years)
Secondary	Post progression survival (PPS) of the first, second and third line chemotherapy		From the date of first documented disease progression in each line of chemotherapy until date of death from any cause (up to 5 years)
Secondary	Time to treatment failure (TTF) of the first, second and third line chemotherapy		From starting date of each line of chemotherapy until date of discontinuation of study treatment for any reason including disease progression, treatment toxicity or death (up to 5 years)
Secondary	New metastasis-free survival (nMFS) of the first, second and third line chemotherapy		From starting date of each line of chemotherapy until the date of first documented disease progression due to appearance of a new metastasis or date of death from any cause, whichever comes first (up to 5 years)
Secondary	Assessment and comparison of Quality Adjusted Life Years (QALYs) in the first, second and third line chemotherapy, using Japanese version of the EQ-5D-5L value set		From date of the baseline QALYs assessment in each line of chemotherapy until the last date of each line of chemotherapy (up to 5 years)
Secondary	Serious adverse events		Up to 5 years